75% ARR Growth Drives Revenue & Profit Visibility

Summary by AI BETAClose X

Diaceutics PLC reported a strong first half of 2026, with revenue growing 22% on a constant currency basis to £17.5 million, driven by a significant 75% increase in Annual Recurring Revenue (ARR) to £28.8 million. The company's order book stands at £43.7 million, with £15.7 million contracted for the second half of 2026, providing 91% revenue visibility for the full year. Gross margin is expected to be 87%, and Adjusted EBITDA is projected at £1.1 million. Diaceutics maintains a strong balance sheet with £8.1 million in cash and no debt, positioning it well to fund its growth strategy.

Disclaimer*

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings